1. New Obser vations in Idiopathic
Pulmonar y Fibrosis (IPF)
Unpredictability: The Nature of IPF
Even IPF patients with relatively mild lung function impairment
and stable disease may be at significant risk of death. In the
largest controlled clinical trial of patients with IPF, 43%
of deaths occurred in patients with stable lung disease.1*
New data †: Earlier-stage IPF patients had risk of death ‡
similar to those with more advanced disease 1
n = 168 MORTALITY (Over 12 months)
Baseline % Predicted FVC Deaths/Total Pts %
≥80 3/19 16
70-79 6/33 18
60-69 5/44 11
50-59 12/65 19
40-49 2/7 29
Early referral to a randomized clinical trial may be a good option
for patients recently diagnosed with IPF, given that IPF has low
survival rates and no approved therapy. Pulmonary rehabilitation,
(often combined with oxygen therapy) and lung transplantation
are other options.2
InterMune is dedicated to the clearer understanding of IPF, working
to advance care for patients and physicians urgently awaiting an
effective treatment.
* Patients were monitored at 3-month intervals and disease progression was defined as either an increase of at least 5 mm Hg in A-aPO2 or a decrease of at least 10% in predicted % FVC
compared with baseline.
The future of IPF
† In untreated patients with IPF.
‡ 82% of deaths were due to respiratory events; 71% of deaths were due to respiratory insufficiency or progression of IPF.
References: 1. Data on file. InterMune, Inc., Brisbane, Calif, 2004. 2. American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and
treatment. International consensus statement. Am J Respir Crit Care Med. 2000;161:646-664. 3280 Bayshore Boulevard, Brisbane, CA 94005
www.intermune.com ©2005 InterMune, Inc. MAIPF148.03.05

2. 10,000,000
Americans have osteoporosis, which causes
700,000
vertebral compression fractures each year; at least
500,000
vertebral compression fractures go undiagnosed annually
If you are at risk for osteoporosis,
there’s a lot on your back
A recent report by the US Surgeon General warns that by the
year 2020, half of all Americans over 50 will be at risk for fractures.
One of the most debilitating, a vertebral compression fracture
(VCF), occurs when a bone in the spinal column weakens and
collapses. Incredibly, the majority of people with VCFs don’t realize
it, often mistaking back pain for a slipped disk or pulled muscle.
What’s worse, if left untreated, VCFs can lead to a pronounced
curvature of the spine (kyphosis), resulting in severe back pain,
reduced activity, and serious medical complications.
Kyphoplasty lifts the burden of VCF
The good news is that a minimally invasive treatment known
as Balloon Kyphoplasty can repair VCFs. Successfully performed
on over 100,000 people worldwide, this treatment has been
For more information on shown to reduce back pain, restore height, and increase mobility.
Balloon Kyphoplasty, If you’re at risk for osteoporosis, talk to your doctor about
call 1-888-645-4444 or visit VCFs and Balloon Kyphoplasty. It’ll take a load off your mind.
www.kyphon.com. And your back.
Although the complication rate has been demonstrated to be low, as with most surgical procedures there are
associated risks, including serious complications. Be sure to consult your doctor for a full discussion of the risks.
Kyphon is a registered trademark, and Ahead of the Curve is a trademark, of Kyphon Inc. © 2005 Kyphon Inc. All rights reserved. XXXXXXXXXX-XX

3. V E R T E B R A L
C O M P R E S S I O N
F R A C T U R E S
COME DOWN
HARD ON A
WOMAN
Lorem ipsum dolor et iusto odio in dolor
consectetuer adipiscing elit, sed diam non-
ummy nibh euismod tincidunt ut laoreet
dolore magna aliquam erat volutpat. Ut wisi
enim ad minim veniam, quis nostrud exerci
tation ullamcorper suscipit lobortis nisl ut
aliquip dolor in hendrerit
vulputate velit esse molestie consequat.
Kyphoplasty helps women
stand strong against VCF
Balloon Kyphoplasty reduces back pain,
restores height, and improves quality of life.
Vel illum dolore eu feugiat ulla facilisis at
vero eros et accumsan et iusto odio dignis-
sim qui blandit praesent luptatum zzril
delenit augue duis dolore te feugait nulla
dolore magna aliquam erat volutpat. Ut wisi
enim ad minim veniam, quis nostrud exerci
KyphX® Inflatable Bone Tamps Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet
dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea
commodo consequat. Duis autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla
Kyphon
facilisis at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te feugait nulla facilisi.
Ahead of the curve.
Kyphon and KyphX are registered trademarks, and HV-R and Ahead of the Curve are trademarks, of Kyphon Inc. © 2005 Kyphon Inc. All rights reserved. XXXXXXXXXX-XX

4. INTRODUCING
NEW ZMAX COMPLETE.
Captures maximum RTI success with the maximized
compliance of one concentrated dose.
The only single, 2 g dose antibiotic with a long
half-life ensures rapidly achieved high tissue
MAXED concentrations and maintains them in the body.
With Zmax Complete, you can make sure your
OUTCOMES RTI patients capture the best possible outcomes.
MINIMUM THERAPY
MAXED OUTCOMES

5. It only takes one to
MAXIMI E
RTI success.
INTRODUCING NEW ZMAX COMPLETE.
Takes patients to maximum success with the maximized
compliance of one concentrated dose.
It’s the only single, 2g dose antibiotic with a long half-life that ensures rapid high tis-
sue concentrations and maintains them in the body for 10 days.
With Zmax Complete, you can make sure your RTI patients get the best TAKE OUTCOMES
possible outcomes. TO THE MAX

6. RELPAX. HEAD-TO-HEAD SUPERIORITY
OVER SUMATRIPTAN.
Relpax: Superior migraine relief versus sumapriptan gets more patients feeling good again.
• Superior migraine relief versus sumatriptan 100 mg
• Rapid and sustained response for up to 24 hours*
*For some patients, relief was seen as early as 30 minutes. For most, relief was seen in 2 hours.
RELPAX is indicated for the acute treatment of migraine with or without aura in adults.
The maximum recommended single dose of RELPAX is 40 mg.
.
RELPAX should not be given to patients with ischemic heart disease or other significant underlying
cardiovascular disease.
RELPAX should not be used within at least 72 hours of treatment with the following potent CYP3A4
inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir.
Please see brief summary of prescribing information on next page A REAL DIFFERENCE IN RELIEF.

7. WITH SUPERIORITY TO SUMATRIPTAN,
RELPAX GIVES RELIEF THAT’LL GO
RIGHT TO HER HEAD.
In head-to head trials, Relpax delivered superior migraine relief.
• Superior migraine relief versus sumatriptan 100 mg
• Rapid and sustained response for up to 24 hours*
*For some patients, relief was seen as early as 30 minutes. For most, relief was seen in 2 hours.
RELPAX is indicated for the acute treatment of migraine with or without aura in adults.
The maximum recommended single dose of RELPAX is 40 mg. RELPAX should not be given to
.
patients with ischemic heart disease or other significant underlying cardiovascular disease.
RELPAX should not be used within at least 72 hours of treatment with the following potent CYP3A4
inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir.
Please see brief summary of prescribing information on next page PROVEN RELIEF

8. Master precision pain relief.
500
500
Introducing Prexige. The highly selective COX-2 N E W
that masters the art of power and safety.
• The most selective COX-2 inhibitor available (COX-2 to COX-1 ratio of 515:1)
• Class-leading GI and CV safety profile demonstrated in TARGET, the largest
OA outcomes trial
• Proven, powerful pain relief demonstrated in head-to-head trials vs leading
COX-2 selective inhibitors

9. Lorem ipsum 500 to 1
500 Lorem ipsum 500 to 1
Lorem ipsum 500 to 1
500
Lorem ipsum 500 to 1
Lorem ipsum 500 to 1
Lorem ipsum 500 to 1
500
HIT T H E PA I N .
MISS THE RISKS.
500
Introducing Prexige. High COX-2 selectivity aims power N E W
only at pain, to protect the system.
• The most selective COX-2 inhibitor available (COX-2 to COX-1 ratio of 515:1)
• Class-leading GI and CV safety profile demonstrated in TARGET, the largest
OA outcomes trial
• Proven, powerful pain relief demonstrated in head-to-head trials vs leading
COX-2 selective inhibitors

13. Guidant leads. Life follows.
1980 First Implanted Defibrillator
1999 CADILLAC Trial Reported
1999 First Implanted Cardiac Resynchronization Therapy Defibrillator
2001 MADIT II Trial Halted
2002 COMPANION Trial Halted
2003 ADVANCENTSM Registry Started
Guidant. Clinical and technological leadership that is helping you
advance the standard of cardiovascular care for more patients.
w w w. g u i d a n t . c o m 1-800-CARDIAC

15. more time
© 2004 Guidant Corporation
in the game for post-MI patients like Bob
Bob was a MADIT II–enrolled patient who received a Guidant ICD in 2000.
Guidant ICDs increase survival over time
for post-MI patients with EF ≤30%
New evidence from MADIT II* Screen for
prior MI
In addition to the 31% reduction in risk of death demonstrated by MADIT II (P=.016),
post-myocardial infarction (MI) patients with ejection fraction (EF) ≤30% receiving Measure for
Guidant implantable cardioverter defibrillators (ICDs) plus optimal pharmacologic EF ≤30%
therapy (OPT) showed1,2:
• Increased survival benefits as time post-MI (>18 months) increased (P=.001) Refer for
ICD therapy
• Reduced mortality risk over time—up to 15 years post-MI
When you refer a post-MI patient for Guidant ICD therapy based on EF, you make a referral for more life.
*Multicenter Automatic Defibrillator Implantation Trial II.
References: 1. Wilber DJ, Zareba W, Hall WJ, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082-1084. 2. Moss AJ, Zareba W, Hall WJ, et al, for the
Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
Please see complete Instructions for Use on adjacent page. 1.800.CARDIAC www.guidant.com

16. HOW HIGH CAN
HE GOES DEPEND ON
H OW LOW
HE GOES
P O W E R F U L L D L- C A N D T G R E D U C T I O N S , A T E V E R Y D O S E *
– 19 %
TG
L D L- C –26%
–39%
–29%
–43%
–37%
–50%
–60%
10mg 20mg 40mg 80mg
* Pooled results (mean) from 2 multicenter, placebo-controlled, dose-response
studies in patients with hypercholesterolemia.
† Recommended for patients who require LDL-C reduction >45%. P<.05 vs placebo
D I E T, E X E R C I S E , A N D L I P I T O R H E L P G E T Y O U R
PAT I E N T S T O T H E I R L I P I D G O A L S

17. Full of satisfaction.
Not full of medication.
Powerful, fast-acting ED therapy that builds
up his performance, not excess medication.
Powerful efficacy from erection to intercourse —
Nothing has been shown to work better
Rapid onset in just 14 minutes* —
Nothing has been shown to work faster POWER HE NEEDS.
Ideal 4-hour duration that matches the NOTHING HE DOESN’T.
sexual habits of most men
VIAGRA is indicated for the treatment of erectile dysfunction patients with underlying cardiovascular disease or other more
(ED). The use of VIAGRA and organic nitrates in any form, unusual conditions could be adversely affected by vasodilatory
at any time, is contraindicated. The most common side effects effects, especially in combination with sexual activity. Patients
of VIAGRA were headache (16%), flushing (10%), and dyspepsia with the following characteristics (recent serious cardiovascular
(7%). Adverse events, including visual effects (3%), were events, hypotension or uncontrolled hypertension, or retinitis
generally transient and mild to moderate. Before treating ED, pigmentosa) did not participate in preapproval clinical trials. In
physicians should consider the impact of resuming sexual these patients, physicians should prescribe VIAGRA with caution.
activity and the mild and transient vasodilatory effects of VIAGRA
on blood pressure. Physicians should carefully consider whether For more information, visit www.viagraMD.com
*Study included previous VIAGRA responders who took 100 mg at least 2 hours after eating (N=228). For most men, VIAGRA works in as quickly as 30 minutes.

18. Featherbed. As experienced by a neuropathic pain sufferer.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis
tincidunt ut laoreet dolore magna aliquam erat VO LUT PAT . Ut wisi enim ad minim veniam, Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod
quis N O ST R U D exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo tincidunt ut laoreet dolore magna aliquam erat VO LUTPAT .
consequat. Duis autem vel eum iriure D O LO R in hendrerit in vulputate velit esse molestie
consequat, vel illum dolore eu F E U G I AT nulla facilisis at vero eros et accumsan et iusto odio.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod Change perceptions with a prescription.

19. Postherpetic neuralgia is pain
on a different scale.
It calls for a different
kind of relief.
NEURONTIN: The only FDA-approved
oral medication for the management
of postherpetic neuralgia in adults.
✦ 1800 mg/day (600 mg tid) provides significant
relief of postherpetic neuralgia
✦ Significant pain relief proven in 2 randomized,
double-blind, placebo-controlled, multicenter trials
✦ Significant reduction of pain as early as week 1
✦ Simple, safe pharmacokinetics—not hepatically
metabolized or protein bound
NEURONTIN is indicated for the management of postherpetic neuralgia in adults. NEURONTIN is
contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.
The most commonly observed adverse events associated with the use of NEURONTIN in adults
compared to placebo were dizziness (28.0% vs 7.5%), somnolence (21.4% vs 5.3%),
peripheral edema (8.3% vs 2.2%), asthenia (5.7% vs 4.8%), and diarrhea (5.7% vs 3.1%).
Please see brief summary of full prescribing information on adjacent pages. A different kind of relief.

20. SHE’S THE STRONG SILENT TYPE.
LIKE HER NEURONTIN.
Add-on partial seizure control with excellent tolerability
Efficacy in a range of patients
Well tolerated
Effective starting dose
Rapid titration to maximum efficacy
Simple, safe pharmacokinetics
Available in 100-mg, 300-mg, and 400-mg capsules,
600-mg and 800-mg tablets, and an oral solution
NEURONTIN is indicated as adjunctive treatment for partial seizures in pediatric patients (3-12 years old) and for partial seizures with and
without secondary generalization in adults (>12 years old). NEURONTIN is contraindicated in patients who have demonstrated hypersensitivity
to the drug or its ingredients. NEURONTIN use in pediatric patients aged 3 to 12 years has been associated with mild to moderate
neuropsychiatric adverse events, including emotional lability, hostility, thought disorder, and hyperkinesia.
In controlled clinical trials, the most common adverse events reported with NEURONTIN vs placebo in adults (>12 years old) were somnolence
(19.3% vs 8.7%), dizziness (17.1% vs 6.9%), ataxia (12.5% vs 5.6%), fatigue (11.0% vs 5.0%), and nystagmus (8.3% vs 4.0%); the most common adverse
events in pediatric patients (3-12 years old) were viral infection (10.9% vs 3.1%), fever (10.1% vs 3.1%), nausea and/or vomiting (8.4% vs 7.0%),
somnolence (8.4% vs 4.7%), and hostility (7.6% vs 2.3%).
Please see brief summary of full prescribing information on adjacent pages.